Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Toxicokinetics of remofovir in mice, rats and monkeys after repeated oral administrations

  • At: 2004 FIP Congress in New Orleans (USA)
  • Type: Poster
  • By: XU, Christine (Valeant Pharmaceuticals International, Drug Development, Costa Mesa, United States of America)
  • Co-author(s): Vitarella (Valeant Pharmaceuticals International, COSTA MESA, United States of America)
    Lin (Valeant Pharmaceuticals International, COSTA MESA, United States of America)
    Yeh (Valeant Pharmaceuticals International, COSTA MESA, United States of America)
  • Abstract:

    Aim: Remofovir is an orally bioavailable liver-targeting prodrug of PMEA that inhibits HBV DNA replication. These studies were to evaluate the toxicokinetics of remofovir and PMEA following daily oral doses of remofovir for 28 days to mice, rats and monkeys, and to compare the exposure levels of PMEA in different species. Methods: Animals received ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses